This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Albugon, GSK716155, Syncria, Eperzan (EU)
Description: Syncria is a long-acting form of glucagon-like peptide-1 (GLP-1). It involves a recombinant fusion product of GLP-1 fused to recombinant human albumin, using HGS' proprietary technology. The primary obstacle to the use of GLP-1 as a therapeutic for diabetes is its extremely short half-life of about five minutes in the body. Syncria is given by injection.
GLP-1 is an incretin hormone secreted in the small intestine and colon in response to food intake. It enhances insulin secretion when glucose levels are high, suppresses inappropriate glucagons secretion (glucagon has the opposite effect of insulin), slows gastric emptying (slowing entry of ingested nutrients into the bloodstream, hence limiting post-prandial glucose), and via actions on the brain is thought to promote satiety.
At the 2013 JPM Global Healthcare Conference, a company official indicated that the drug will be administered through a pen device which requires three clicks, a 15 minute wait, then injection through a 30 gauge needle.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
In October 2004, GSK acquired exclusive worldwide rights to develop and commercialize Syncria for all human therapeutic and prophylactic applications. Under the agreement, Human Genome Sciences (HGS) received an upfront fee and is entitled to clinical development and commercial milestone payments that could amount to as much as $183 million, and additional milestones for other indications developed. HGS also will receive royalties on the annual net sales of any products developed and commercialized under the agreement.
In April 2008, Human Genome Sciences announced that it reacquired rights to the TRAIL receptor antibodies HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab) from GlaxoSmithKline (GSK), in return for a reduction in royalties due to HGS if Syncria (albiglutide) is commercialized. The royalties to HGS are now in the single-digit range.
In July 2012, GlaxoSmithKline and Human Genome Sciences entered into...See full deal structure in Biomedtracker
Additional information available to subscribers only: